Coverage / LON:FARN / Trade Card

LON:FARN

Faron Pharmaceuticals Oy

SPECULATIVE BUY 2026-08-08 Data 35 days old 40.90p Healthcare - BiotechnologyAWAIT ENTRY
ACTIONABLEMethodology gates passed
49

Position levels

Currenttoday
40.90p
Buy <=wait / entry
28.33p
Trim >=take some off
55.00p
Thesis breakThe thesis would be invalidated by a clearly negative BEXMAB efficacy or safety ...
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case16%100 / 10016.0
Base case48%62 / 10029.8
Bear case36%10 / 1003.6
Weighted conviction49 / 100 - SPECULATIVE BUY

Top risks

  • Binary clinical outcome risk for Bexmarilimab in Phase I/II trials
  • Capital dependency with cash reach only to mid-2026 and no revenue
  • Pipeline limited to immuno-oncology asset with no current partnerships or licensing deals evidenced
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.